financetom
Business
financetom
/
Business
/
Phosphate fertilizer producer Itafos Q3 revenue rises 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Phosphate fertilizer producer Itafos Q3 revenue rises 
Nov 5, 2025 2:45 PM

Overview

* Itafos ( ITFS ) Q3 revenue rises to $152.8 mln, driven by strong phosphate market dynamics

* Adjusted EBITDA for Q3 2025 reaches $48.9 mln, highest since Q4 2022

* Company announces CAD$0.17/share special dividend following Araxá Project sale

Outlook

* Company expects modest softening in phosphate prices through Q4 2025

* Itafos ( ITFS ) revises FY 2025 sales volumes to 345-355 thousand tonnes P2O5

* Company anticipates steady global phosphate consumption despite US affordability challenges

Result Drivers

* PRODUCTION RATES - Sustained high production rates at Conda contributed to strong Q3 results

* NEW PRODUCTS - Introduction of new dry fertilizer products at Arraias supported sales volume growth

* PHOSPHATE MARKET - Strong phosphate market dynamics drove higher realized prices, boosting revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $152.8

Revenue mln

Q3 Net $36.2

Income mln

Q3 $48.9

Adjusted mln

EBITDA

Q3 Capex $21.6

mln

Analyst Coverage

* The one available analyst rating on the shares is "strong buy"

* The average consensus recommendation for the agricultural chemicals peer group is "buy."

* Wall Street's median 12-month price target for Itafos Inc ( ITFS ) is C$5.00, about 33.2% above its November 4 closing price of C$3.34

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Is Thor Industries Stock Diving After Q2 Results?
Why Is Thor Industries Stock Diving After Q2 Results?
Mar 6, 2024
Thor Industries, Inc. ( THO ) shares are trading lower on Wednesday. The company reported second-quarter earnings per share of 34 cents, missing the analyst consensus of 67 cents.  Quarterly revenues of $2.207 billion missed the consensus estimate of $2.267 billion. North American Towable RV net sales were down 11.9% for the second quarter, while North American Motorized RV net sales decreased 22.8%....
Ross Stores Better-Than-Expected Fiscal Q4 Due to Topline, GM Outperformance, Morgan Stanley Says
Ross Stores Better-Than-Expected Fiscal Q4 Due to Topline, GM Outperformance, Morgan Stanley Says
Mar 6, 2024
11:25 AM EST, 03/06/2024 (MT Newswires) -- Ross Stores ( ROST ) better-than-expected fiscal Q4 earnings were due to topline and GM outperformance, Morgan Stanley said in a note to clients Wednesday. The EPS beat was partially offset by rising selling, general and administrative costs, however, the report added. Highlights of the quarter included underlying sales growth, current apparel category...
E.l.f. Beauty's Biggest Near-Term Opportunity Remains Shelf Space Expansions at Walmart, BofA Says
E.l.f. Beauty's Biggest Near-Term Opportunity Remains Shelf Space Expansions at Walmart, BofA Says
Mar 6, 2024
11:26 AM EST, 03/06/2024 (MT Newswires) -- E.l.f. Beauty's (ELF) biggest near-term opportunity continues to be shelf space expansions at Walmart ( WMT ) , BofA Securities said Wednesday in a report. The cosmetic company presently has about 8 feet of shelf space at Walmart ( WMT ) and 3 feet at the drug channel, compared with 13 feet at...
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference
Mar 6, 2024
11:16 AM EST, 03/06/2024 (MT Newswires) -- BriaCell Therapeutics Corp. ( BCTX ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, says it will be presenting three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10 at San Diego Convention Center, San Diego, CA. Price: 4.54, Change: -0.03,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved